Ksander G M, Ghai R D, deJesus R, Diefenbacher C G, Yuan A, Berry C, Sakane Y, Trapani A
Research Department, CIBA-GEIGY Corporation, Summit, New Jersey 07901, USA.
J Med Chem. 1995 May 12;38(10):1689-700. doi: 10.1021/jm00010a014.
The synthesis of three series of dicarboxylic acid dipeptide neutral endopeptidase 24.11 (NEP) inhibitors is described. In particular, the amino butyramide 21a exhibited potent NEP inhibitory activity (IC50 = 5.0 nM) in vitro and in vivo. Blood levels of 21a were determined using an ex vivo method by measuring plasma inhibitory activity in conscious rats, mongrel dogs, and cynomolgus monkeys. Free drug concentrations were 10-1500 times greater than the inhibitory constant for NEP over the course of a 6 h experiment. A good correlation of free drug concentrations was obtained when comparing values determined by the ex vivo analysis to those calculated from direct HPLC measurements. Plasma atrial natriuretic factor (exogenous) levels were elevated in rats and dogs after oral administration of 19a. Urinary volume and urinary sodium excretion were also potentiated in anesthetized dogs treated with 21a.
描述了三个系列二羧酸二肽中性内肽酶24.11(NEP)抑制剂的合成。特别地,氨基丁酰胺21a在体外和体内均表现出强效的NEP抑制活性(IC50 = 5.0 nM)。通过测量清醒大鼠、杂种犬和食蟹猴的血浆抑制活性,采用离体方法测定了21a的血药浓度。在6小时的实验过程中,游离药物浓度比NEP的抑制常数高10 - 1500倍。将离体分析测定的值与直接HPLC测量计算的值进行比较时,游离药物浓度具有良好的相关性。口服19a后,大鼠和犬的血浆心房利钠因子(外源性)水平升高。用21a治疗的麻醉犬的尿量和尿钠排泄也增强。